The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: Results of a comparative analysis

Leukemia Research

Volumn 37, Issue 8, 2013, Pages 943-947

  Molica, Stefano ^a   Giannarelli, Diana ^b   Gentile, Massimo ^c   Cutrona, Giovanna ^d   Di Renzo, Nicola ^e   Di Raimondo, Francesco ^f   Neri, Antonino ^g   Federico, Massimo ^h   Ferrarini, Manlio ^d   Morabito, Fortunato ^c  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c Azienda Ospedaliera   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e ASL Lecce   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Early CLL; Prognostic validation model; Time to first treatment

Indexed keywords

BETA 2 MICROGLOBULIN; CD38 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; LACTATE DEHYDROGENASE; PROTEIN KINASE ZAP 70; THYMIDINE KINASE;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PROGNOSIS; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE STUDY; CORRELATION ANALYSIS; EXTERNAL VALIDITY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GERMAN SCORE; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOGLOBULIN VARIABLE REGION; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MD ANDERSON CANCER CENTER SCORE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; TIME TO TREATMENT; TRISOMY 12; WESTERN BLOTTING;

ADULT; AGED; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; ROC CURVE; TIME FACTORS;

EID: 84879781344     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.02.016     Document Type: Article

References (20)

1. Abrisqueta P., Pereira A., Rozman C., Aymerich M., Giné E., Moreno C., et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood 2009, 114(10):2044-2050.
2. Molica S., Levato D. What is changing in the natural history of chronic lymphocytic leukemia?. Haematologica 2001, 86(1):8-12.
3. Wierda W.G., O'Brien S., Wang X., et al. Multivariate model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol 2011, 29(31):4088-4095.
4. Molica S., Mauro F.R., Callea V., et al. The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. Haematologica 2010, 95(3):464-469.
5. Morabito F., Cutrona G., Gentile M., et al. Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. Br J Haematol 2009, 146(1):44-53.
6. Letestu R., Lévy V., Eclache V., et al. Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters. Blood 2010, 116(22):4588-4590.
7. Pepper C., Majid A., Lin T.T., et al. Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol 2012, 156(4):499-507.
8. Molica S., Giannarelli D., Gentile M., et al. External validation on a prospective basis of a nomogram for predicting time to first treatment in patients with chronic lymphocytic leukemia. Cancer 2012, (December). [Epub ahead of print]. 10.1002/cncr.27900.
9. Bahlo J., Pflug N., Elter T., et al. Proposal of a prognostic score for previously untreated patients with chronic lymphocytic leukemia based on an overall survival analysis of three German CLL Study Group Phase III trials. Blood 2011, 118(Suppl. 1). abstr. 2831.
10. Cheson B.D., Bennett J.M., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996, 87(12):4990-4997.
11. Hallek M., Cheson B.D., Catovsky D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111(12):5446-5456.
12. Cutrona G., Colombo M., Matis S., et al. Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells. Haematologica 2008, 93(3):413-422.
13. Fais F., Ghiotto F., Hashimoto S., et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998, 102(8):1515-1525.
14. Fabris S., Mosca L., Todoerti K., et al. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 2008, 47(9):781-793.
15. Harrell F.E., Lee K.L., Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996, 15(4):361-387.
16. Heagerty P.J., Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005, 61(1):92-105.
17. Wierda W.G., O'Brien S., Wang X., et al. Prognostic nomo-gram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007, 109:4679-4685.
18. Molica S. Survival and disease-progression studies in early chronic lymphocytic leukemia. Blood 1991, 78:895-899.
19. Rossi D., Gaidano G. Molecular genetics of high-risk chronic lymphocytic leukemia. Expert Rev Hematol 2012, 5(December (6)):593-602.
20. Rossi D., Rasi S., Spina V., et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013, (January). [Epub ahead of print].